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A B S T R A C T
Purpose: To physically and cytogenetically screen medical personnel of Department of Endocrinology and
Nuclear Medicine, Holy Cross Cancer Center, Kielce, Poland (DENM) who are occupationally exposed to 131I.
Materials and Methods: The exposure was monitored by whole-body and finger ring dosimeters. The thyroid
iodine intake was measured by a whole-body spectrometer equipped with two semiconductor gamma radiation
detectors. A cytokinesis-block micronucleus assay and the premature chromosome condensation technique were
used to assess the aberration score. Cytogenetic analyses were carried out on a group of 29 workers and were
compared to 32 controls (healthy donors), matched for gender and age.
Results: On average, the exposed group showed a significantly higher frequency of genetic damage and a higher
proliferation index compared to the control group. Smoking status, age and duration of exposure influenced the
observed effects in both groups. No differences in measured biomarkers were observed after stratification of the
exposed group into two subgroups based on the measured 131I activity below and above 6 Bq.
Conclusion: The findings suggest that radiation protection principles based on whole-body and finger ring do-
simetry, supported by activity measurements with a whole-body spectrometer, may be insufficient to monitor
the absorbed dose estimation of the nuclear medicine staff who are occupationally exposed to 131I. Furthermore,
their future health risks are influenced by confounders. Direct assessments comparing physical and biological
dose estimations on the larger group are needed to accurately monitor occupational radiation exposure.
1. Introduction
Previous studies using a whole-body spectrometer at Institute of
Nuclear Physics, Polish Academy of Sciences in Kraków (IFJ PAN) have
shown that the medicine staff may have unavoidably absorbed different
doses of iodine-131 (131I, radioiodine) in the thyroid depending on their
profession [1–6]. Iodine-131 is an important radioisotope that is se-
lectively taken up by the thyroid gland and is popularly used in medical
diagnostics and treatment procedures with a short radioactive half-life
decay (T1/2=8.03 d) [3,4]. In the course of their duties, employees
can be externally exposed to iodine when the source of radiation is the
patient; radioactive iodine is typically taken in pill form (rarely as a
solution) and is internally up taken by breathing air that is exhaled by
patients treated with these radiopharmaceuticals [3]. Our previous
studies have shown that exposure to radioiodine can lead to different
extents of cellular DNA damage, not only in thyroid cells but also in
other tissues (i.e., peripheral blood lymphocytes) [6]. In accordance
with the Polish law, the exposure monitoring in nuclear medicine units
is performed only with thermoluminescent dosimeters (TLDs) [1,4].
However, this type of monitoring does not provide any data on the
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doses incorporated into the thyroid gland or the total absorbed dose in
the whole organism taking into account individual cell responses in-
fluenced by confounders [1,4,5].
In the light of previously published results [1,4,6], the aim of this
study was to monitor the chromosomal damage and proliferation index
in whole peripheral blood lymphocytes (HPBLs) of a group of medical
staff exposed to 131I by using a cytokinesis-block micronucleus test
(CBMN) and the premature chromosome condensation technique (PCC)
in comparison with results obtained by using a whole-body spectro-
meter and TLD measurements to assess the genotoxic potential of the
exposure. We also investigated how other confounders such as age,
duration of exposure and smoking status influenced the observed ef-
fects.
The frequency of micronuclei (MNi) and excess PCC fragments
measured with the CBMN and PCC techniques are internationally ac-
cepted biomarkers of individual dose assessment in the field of biolo-
gical dosimetry and radiation protection [7–11]. They are used to
evaluate in vivo radiation exposure of occupational, medical and acci-
dentally exposed individuals, usually in their HPBLs [7–11]. The ad-
vantage of these tests consists of providing simultaneous information on
chromosomal damage and the rate of lymphocyte proliferation [7,8].
2. Materials and methods
2.1. Characteristics of study populations and blood collection
In the department where our study took place, 131I is administered
to patients to perform thyroid scintigraphy, treat hyperthyroidism and
thyroid cancer treatment. The exposed group contained 29 employees
(2 men and 27 women) of DENM. The men were 45 and 48 years old at
the time of the measurement, whereas the women were aged 40–56
years (average age: 46.9 ± 4.5 years). The detailed characteristics of
the exposed group is presented in Table 1 in the results section. The
research was approved by the Bioethics Committee of the Regional
Medical Board in Kraków (No. 111/KBL/OIL/2015). The same selection
criteria were used for the control group. A total of 32 controls (1 male,
31 females; mean age 48.0 ± 8.6 years) were not exposed to radio-
pharmaceuticals and were recruited from internal medicine wards of
the same hospital. Each participant in the study was asked to complete
a survey questionnaire including personal data, gender and age, occu-
pational activity (also in the past) and data on smoking habits, diet and
previous exposure to radiation. Each of the examined subjects was in-
formed about the scope and purpose of the investigation and gave their
consent.
The peripheral blood samples from exposed and control subjects
were collected in heparinized vacutainers by phlebotomy at the be-
ginning of a working day at the end of 2017 (exposed group) and at the
beginning of 2018 (control group). The samples were transported im-
mediately to the laboratory of IFJ PAN within 2 h, at ambient tem-
perature and were then immediately processed.
2.2. Cytokinesis-block micronucleus assay
The cytokinesis-block micronucleus assay was performed according
to Fenech [8], as previously described [7].
All slides were coded and blinded to the scorer. The slides were
analyzed for micronuclei frequency according to the criteria described
by Fenech [8].
2.3. Premature chromosome condensation test
The cultures were treated similar to those used in the CBMN assay,
following the IAEA guidelines and a previously published data [9,10].
Instead of cytochalasin-B, calyculin A (50 nM) was added to the culture
medium exactly 30min before ending the culturing process (48 h). Cell
finding and image capturing were performed on a Metafer4 scanning
Table 1
Data of the exposed group, including age, profession, gender, duration of exposure, measured 131I thyroid activity and doses [mSv] measured by whole-body
dosimeter (DI) and finger ring dosimeter (PI) for 2016–2017.
Subject code Age [y] Profession Gender Duration of exposure [y] 131I thyroid activity [Bq] DI PI DI PI
2016 2017
1 42 Cleaner F 20 152 ± 40 <0.40 – <0.40 –
2 47 Nurse F 23 – <0.40 – <0.40 –
3 46 Medical doctor F 21 < 5 <0.40 – <0.40 –
4 48 Cleaner F 20 91 ± 24 <0.40 – <0.40 –
5 54 Nurse F 33 < 5 <0.40 – <0.40 –
6 51 Medical doctor F 27 < 5 <0.40 – <0.40 –
7 45 Nurse F 21 < 5 <0.40 – <0.40 –
8 52 Nurse F 30 < 5 <0.40 – <0.40 –
9 54 Technician F 30 107 ± 28 0.72 3 0.77 1.77
10 48 Technician M 22 217 ± 56 <0.40 0.92 <0.40 7.95
11 52 Nurse F 30 < 5 2.31 – <0.40 –
12 43 Nurse F 24 < 5 <0.40 – <0.40 –
13 53 Medical doctor F 30 < 5 <0.40 – <0.40 –
14 45 Nurse F 22 < 5 <0.40 – <0.40 –
15 41 Nurse F 20 66 ± 17 <0.40 – <0.40 –
16 45 Nurse F 22 38 ± 10 <0.40 – <0.40 –
17 41 Medical doctor F 15 – <0.40 – <0.40 –
18 41 Medical doctor F 14 – <0.40 – <0.40 –
19 45 Medical doctor M 20 – <0.40 – <0.40 –
20 41 Nurse F 19 < 5 <0.40 – <0.40 –
21 50 Nurse F 26 < 5 <0.40 – <0.40 –
22 47 Cleaner F 25 – – – – –
23 56 Nurse F 36 – <0.40 – <0.40 –
24 48 Nurse F 25 < 6 ± 6 0.42 – <0.40 –
25 43 Cleaner F 25 5 ± 2 – – – –
26 49 Medical doctor F 24 – <0.40 – <0.40 –
27 44 Nurse F 20 16 ± 5 <0.40 – <0.40 –
28 40 Nurse F 14 < 5 <0.40 – <0.40 –
29 49 Nurse F 30 < 5 <0.40 – <0.40 –
DI - whole-body dosimeter, PI - finger ring dosimeter, F- female, M- male.
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system equipped with a Zeiss Axio Imager Z2 microscope (MetaSys-
tems™, Altlussheim, Germany).
2.4. 131I activity measurements
131I thyroid activity measurements in the occupationally exposed
group were performed with the whole-body spectrometer a few weeks
prior to blood collection [1]. More detailed information concerning the
methodology of the measurements and the dose assessments can be
found in Brudecki at al. [1].
2.5. Whole-body dose estimation
Doses for 2016 and 2017 were measured using a whole-body dosi-
meter (DI) and a finger ring dosimeter (PI) provided by Laboratory of
Individual and Environmental Dosimetry (LADIS) that were accredited
to the EN-PN-ISO/IEC 17025 standard by Polish Centre for
Accreditation. In all measurements, the individual TLDs were used to
measure the operational value Hp(10) and Hp(0.07) [12].
2.6. Statistical analysis
The data were analyzed and presented graphically using Microsoft
Office Excel 2013 and Statistica 13 (StatSoft, Tulsa, OK, USA). The
various biomarkers were measured for each individual. The number of
BNs (binucleated cells) with MNi and the MNi frequency were assessed
based on the analysis of 1000 BN cells. To assess the lymphocyte pro-
liferation rate, the nuclear division index (NDI) was calculated for the
first 500 cells according to Fenech et al. [8]. The PCC fragments per cell
in excess of 46 PCC chromosomes for each donor were scored in 100
G2/M PCC-phase cells [9,10].
The standard deviation (S.D.) was calculated for all measured bio-
markers. Student’s t-test and the Mann-Whitney rank–sum test for
comparison of the biomarkers between the studied groups were used
depending on the normality of the distributed biomarkers as verified by
the Shapiro-Wilk test. P values of< 0.05 were considered to be sig-
nificant and are indicated in the text. Linear regression analysis was
used to assess the effects of confounding factors such as age and the
duration of exposure on the induction of cytogenetic effects.
3. Results
Table 1 presents a summary for every subject in the exposed group
as follows: age, profession, gender, years of exposure, measured 131I
thyroid activity and doses [mSv] by whole-body dosimeter (DI) and
finger ring dosimeter (PI) for 2 years (2016–2017). For 13 subjects, the
thyroid 131I activity measured in 2016 was below the detection limit
(DL < 5 Bq of 131I), for another 7 we did not measure the activity.
Among the remaining 9 individuals, the measured activities were found
to vary between (5 ± 2) Bq and (217 ± 56) Bq for the cleaning staff
members and nuclear technicians, respectively (Table 1).
Measurements were made via whole-body dosimeters (DI) for the
years 2016 and 2017 and showed that 24 subjects had Hp(10) values
lower than 0.4 mSv for 2016, and 26 subjects were below this level
considering the 2017 year. For 3 workers (codes 9, 11, 24), higher Hp
(10) values were observed in for 2016 (0.72, 2.31, 0.42), but they did
not exceed the average annual dose limit (20 mSv/y). This dose limit
was stipulated in the 2013/59 Euroatom (2014) directive [13], re-
commended by ICRP (International Commission on Radiological Pro-
tection) and acquired by the Polish law [1]. In the exposed group, for
one donor only (code 9), the Hp(10) value was higher than 0.4 mSv but
was lower than 0.78 for 2017. All presented values for DI and PI are
subtracted from natural background. We did not receive whole-body
dose estimation data based on DI and PI for two subjects. In the case of
finger ring dosimeters (PI), values greater than 0.9 but less than 8.0
mSv were observed during 2016–2017 for two subjects (codes 9 and
10).
Cytogenetic monitoring was performed for all individuals who were
previously monitored for thyroid activity. Table 2 presents the mean
values of the measured biomarkers for both the exposure and control
groups, stratified by smoking status.
Strong variation, indicated by high S.D. values between measured
biomarkers, was observed for both groups (exposed and control).
However, the mean value of cytogenetic damage, presented as the
number of BNMNs, MNi frequency, number of BN cells with different
numbers of MNi (2 and 3) and excess PCC fragments in the exposed
group, was higher than in the control group (Table 2). Also, the nuclear
division index was significantly higher in the exposed group compared
to controls (Table 2). After the groups were stratified based on smoking
status, we observed statistically significant differences between the
exposed and control subjects only in the proliferation index and in the
binucleated cells carrying 2 micronuclei. A higher frequency of excess
PCC fragments in the exposure vs. control group (p < 0.05) was ob-
served only among non-smokers.
We investigated the possible influence of measured I131 activity on
cytogenetic endpoints, assessed with the CBMN and PCC techniques.
Subjects from the exposed group were stratified into two subgroups
according to the measured 131I thyroid activity: Bq>6 (7 donors,
average activity 98.14 ± 17.71) and Bq<6 or those without mea-
surements (22 subjects). There were no differences among all of the
measured biomarkers between these two subgroups. Surprisingly, we
observed higher values of BMMN, MNi/1000, and BN with +1
Table 2











Total 29 24.90 ± 11.56* 27.90 ± 13.29* 22.21 ± 10.19 2.38 ± 2.04** 0.31 ± 0.54*** 3.04 ± 0.86*** 0.43 ± 0.17**
Non-smokers 18 26.61 ± 13.30 30.00 ± 15.44 23.56 ± 11.60 2.72 ± 2.32* 0.33 ± 0.59 3.00 ± 0.89*** 0.41 ± 0.18**
Smokers 11 22.09 ± 7.71 24.45 ± 8.25 20.00 ± 7.31 1.82 ± 1.40** 0.27 ± 0.47 2.36 ± 1.04** 0.47 ± 0.16
Control
Total 32 19.19 ± 6.14 20.31 ± 6.71 18.19 ± 5.95 0.97 ± 1.06 0.03 ± 0.18 1.71 ± 0.11 0.33 ± 0.14
Non-smokers 17 18.94 ± 6.33 20.24 ± 6.97 17.59 ± 6.06 1.29 ± 1.16 0.06 ± 0.24 1.70 ± 0.12 0.28 ± 0.09
Smokers 15 19.47 ± 6.13 20.40 ± 6.64 18.87 ± 5.95 0.60 ± 0.83 0.00 ± 0.00 1.71 ± 0.11 0.38 ± 0.17
S.D. - standard deviation, BNMN - number of BN cells with MNi in 1000 binucleated cells, MNi/1000 BN cells - MNi frequency per 1000 binucleated cells, NDI -
nuclear division index.
* Statistically significant difference (p < 0.05) vs. total control (Student’s t-test).
** Statistically significant difference (p < 0.05) vs. total control (Mann-Whitney U test).
*** Statistically significant difference (p < 0.0001) vs. total control (Mann-Whitney U test).
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(25.91 ± 12.36 vs. 21.71 ± 8.58; 28.95 ± 14.13 vs. 24.57 ± 10.41;
and 23.18 ± 11.01 vs. 20.00 ± 7.31, respectively) in the group with
less activity/not measured vs. activity> 6 Bq. Furthermore, for two
exposed subjects (codes 9 and 10) with a relatively high value of 131I
activity, which was also monitored by finger ring dosimeters, we did
not observe higher values for the measured biomarkers than in others
from the exposed group. By applying linear regression analysis, a po-
sitive correlation was noticed between the age and duration of exposure
and the total number of MNi/1000 and PCC frequency in the exposed
group (Figs. 1a, c, Fig. 2a and c). In the control group, with increasing
age and exposure duration, a slight decrease of MNi was observed
(Figs. 1b and 2b), while excess PCC increased (Figs. 1d and 2d). Our
results also indicated an effect of age and exposure duration on the
nuclear division index for both of the studied groups. As can be ob-
served in Fig. 1e-f and Fig. 2e-f, there was a decrease in proliferation
ability, with similar slopes but the NDI was higher in the exposed group
than in the controls.
4. Discussion
In this study, we cytogenetically and physically monitored a group
of medical staff exposed to 131I to assess the genotoxic potential of
Fig. 1. Relationship between MNi frequency (Fig. 1a and b), excess PCC fragments (Fig. 1c and d), NDI (Fig. 1e and f) and age (years) of exposed and control subjects.
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exposure. We investigated how confounders such as age, duration of
exposure and smoking status may have influenced the observed effects.
Notably, there is a baseline of spontaneous cytogenetic damage in
individuals who were never exposed to radiation. The background of
micronucleus frequencies found in our control subjects is in agreement
with that reported in the literature [7,14]. As a new concept in the
radiation biodosimetry field, in the present study an attempt was made
to estimate the mean value of excess PCC fragments in the control group
using a chemically induced PCC assay. Generally, most of the relevant
studies have presented frequencies of acentric fragments or rings for
one or a few donors (2–5) as a distribution for the dose-response curve
construction [10,15]. The baseline mean value of NDI for the control
group (1.71 ± 0.11) was in agreement with previously published data
[10,16]. For the exposed group, the averaged mean was higher
(3.04 ± 0.86), indicating that viable cells divided faster than in the
control group and completed more than one nuclear division during the
cytokinesis-block phase.
While confirming previous findings to some extent [1,9], the data
we obtained show that the increased level of cytogenetic damage and
the increased proliferation index in the group exposed to 131I is still
Fig. 2. Correlation between duration of exposure to 131I and genotoxic effects (MNi/1000 BN cells, excess PCC fragments and NDI) assessed by linear regression
analysis in the exposed and control groups.
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highly significant for the donor for which we did not observe a higher
level in the physical dosimetry assessment (Tables 1 and 2). This might
indicate that the observed average higher values for the cytogenetic
endpoints in the exposed group result from the accumulation of DNA
damage induced by several factors, and it may not be possible to se-
parate the impact of 131I on the measured values. This suggests that
physical dosimetry measurements alone might be insufficient in re-
flecting the occupationally received exposure, even if the reported
physical values show the whole radiation exposure (monitored in
people exposed to radioiodine at the workplace wearing TLDs all the
time). It may also be caused by the limitations of the epidemiologic
questionnaires that were used, which may bias the reporting values.
Although the subjects responded to the paper questionnaires during a
face-to-face interview, some may conceal information regarding their
exposure in other workplaces or the total duration of exposure. In ad-
dition, nuclear medicine staff might be exposed to other nuclides (e.g.,
Tc-99m, F-18, In-111, I-123, Y-90 and P-32) when performing diag-
nostic and therapeutic procedures.
Importantly, physical dosimetry is routinely used over many years
for monitoring the levels of exposure received by radiation workers [3],
but only biological monitoring provides information about the total,
cumulative dose absorbed during the most recent few years, which can
contribute to a more accurate occupational risk assessment at the in-
dividual or group level [6,18]. We are also aware that the biological
techniques applied in this study have some disadvantages and limita-
tions. One is the lower limit for dose detection of the CBMN assay and
PCC technique that is employed in many laboratories, which is re-
stricted to 0.2–0.5 Gy [9]. To assess the possible overexposure of oc-
cupationally exposed persons using cytogenetic markers appears to be
challenging, because a large number of cells would have to be analyzed
to obtain statistically relevant differences between exposed and control
groups. Furthermore, the radioactive material is heterogeneously dis-
tributed in the body [9]. Direct comparisons of spectrometer results and
physical dosimetry with cytogenetics might be a new route for epide-
miological studies regarding radiation protection principles, but here
we were not able to show a direct dose-effect relationship for those
exposed to different amounts of 131I. The main reason for this was a lack
of 131I thyroid activity data or values that were below the detection
limit for more than half of the group (see Table 1). We consider this a
limitation of this study; however, we believe that this attempt provides
insights for additional and larger studies. To the best of our knowledge,
this research is the first study that has simultaneously measured both
external and internal exposure together with estimating the absorbed
doses by cytogenetic monitoring in the same cases. Individual studies
have been conducted that primarily employed the external monitoring
of 131I by different types of dosimeters [19] or internal measurements
[4,5], as well as biological monitoring alone [9,19]. Based on detection
limit criteria, we assessed the possible influence of the measured I131
activity on cytogenetic endpoints by stratifying the exposed group by
the measured 131I thyroid activity into greater or less than 6 Bq. We
observed higher values of BMMN, MNi/1000 and BN cells with +1 in
the group with less activity/not measured vs. activity> 6 Bq. This
finding indicates that this group of workers shows an impact in the
higher values of the cytogenetic biomarkers, and were unable to find
the reason behind it. Therefore, this should be taken into consideration
in any future studies.
The high variability between individuals found in our study (as
shown by the value of ± S.D.) implies the necessity for biological
monitoring. In this respect, it might be argued that the measured doses
and 131I activities seem to be in accordance with the law and are too
low to have an impact on the health risk [3]. On the other hand, it is
known that the major health risks associated with exposure to iodine-
131 involve the thyroid gland, which concentrates this radionuclide
[20]. Another limitation of this study is that it was difficult to establish
an in-vitro dose-effect relationship between chromosome damage and
exposure to low levels of ionizing radiation [9,21] that can be used to
evaluate partial or the whole-body exposure. Any relationship should
take into consideration the differences in background MNi frequency,
the response variation of individual subjects and other biological var-
iations such as biokinetic parameters that describe isotope intake, up-
take and excretion [1,4,21,22].
The observed results could have arisen due to confounding factors
affecting MNi frequency levels in humans, such as smoking, diet or
environmental exposures [4,13,16,17]. Although we did not stratify
subgroups according to the daily consumption of cigarettes, as has been
done by others [23], our observations are supported by these findings,
suggesting that smoking can affect the level of genetic damage induced
in humans by ionizing radiation. Surprisingly, the frequency of MNi in
the exposed group is higher for non-smokers than for smokers. Many
authors have studied the genotoxic effects of tobacco using the micro-
nucleus assay [9,19,24], but this has shown conflicting data, where
smoking has either influenced or not influenced the lymphocyte re-
sponse that was measured as a cytogenetic endpoint.
Many authors have reported that cytogenetic damage is a very good
indicator of age and duration of exposure [14,25]. These factors may
increase the incidence of genetic damage by an age-related number of
unrepaired DNA strand breaks induced by endogenous or/and exo-
genous factors [24]. Our findings are consistent with other studies that
have performed correlation analysis [6,26], which is a useful statistical
tool in researching the influence of both factors on the incidence of
cytogenetic endpoints. Notably, all relationships presented here re-
present visible tendencies; however, differences are not significant,
probably due to the high variability between individuals and relatively
small sample groups.
The results and discussion presented here are not sufficient for
making strong recommendations, but rather may stimulate further in-
vestigations concerning protective measures in the case of individuals
who have been occupationally exposed to 131I. Our findings support the
conclusions previously put forward by Brudecki et al. [1,4] who in-
dicated that risk evaluation associated with chronic exposure 131I must
be systematic, controlled by physical dosimetry and should be esti-
mated periodically as an integrated radiological protection standard of
nuclear medicine personnel occupationally exposed to 131I.
5. Conclusion
In this study, cytogenetic monitoring together with whole-body
dosimetry and 131I activity measurements were studied in HPBLs of
nuclear medicine staff and compared to a control group. A strong var-
iation between measured biomarkers of the exposed group was ob-
served. The increased chromosome fragments and micronuclei fre-
quencies found in workers indicate potential genetic hazards.
Unfortunately, very little information is available regarding the adverse
human health effects of 131I exposure. These observations, confirmed by
previous findings and suggestions, indicate the need for further studies
with a greater number of exposed individuals, along with in vitro stu-
dies for estimating the impact of 131I exposure on the observed higher
frequency of cytogenetic damage.
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